Kubota Pharmaceutical Holdings Co., Ltd. (TYO:4596) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
Holdings Co., Ltd. (the “Company”) will make a presentation to
analysts of the Company in Tokyo, Japan. The slides for the
analyst presentation will be posted to the Companys website at
http://http://www.kubotaholdings.co.jp/en/ir/index.html and are
furnished as Exhibit 99.1 to this Form 8-K.
is being furnished and shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange
Act, except as shall be expressly set forth by specific reference
in such a filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
||
|
(d) Exhibits.
|
|||
|
Exhibit Number
|
Description
|
||
|
99.1
|
Presentation for FY 2016 Analyst Meeting.
|
||
About Kubota Pharmaceutical Holdings Co., Ltd. (TYO:4596)
Kubota Pharmaceutical Holdings Co., Ltd. is a Japan-based company mainly engaged in the operation and management of subsidiaries. Its subsidiaries are mainly engaged in discovering and developing drug candidates to treat and slow the progression of sight-threatening ophthalmic diseases. The Company operates pharmaceutical development segment. It focuses on the development of oral formulation for age-related macular degeneration (AMD), glaucoma and dry eye syndrome. Kubota Pharmaceutical Holdings Co., Ltd. (TYO:4596) Recent Trading Information
Kubota Pharmaceutical Holdings Co., Ltd. (TYO:4596) closed its last trading session 00.00 at 911.00 with 47,100 shares trading hands.
